T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
Francesco Schettini(Target (United States)), Lucia Del Mastro(Ospedale Policlinico San Martino), Marta Bonotto(University of Udine), Fabio Puglisi(University of Udine), Daniele Generali(University of Trieste), Claudia Bighin(Alleanza Contro il Cancro), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Valentina Guarneri(University of Padua), Grazia Arpino(University of Naples Federico II), PierFranco Conte(University of Modena and Reggio Emilia), Sara Parola, Alessandra Fabi(Agostino Gemelli University Polyclinic), Benedetta Conte(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giacomo Pelizzari(Centro di Riferimento Oncologico), Antonio Frassoldati(University of Ferrara), Antonio Pazzola(Azienda Ospedaliero Universitaria di Sassari), Sabino De Placido, Stefania Russo(National Center for Oncological Hadrontherapy), Matteo Lambertini(Ospedale Policlinico San Martino), Gaia Griguolo(University of North Carolina at Chapel Hill), F. Cognetti(Sapienza University of Rome), Mariavittoria Locci, Giuseppe Buono(Federico II University Hospital), Ferdinando Riccardi(Fatebenefratelli Hospital)
Cited by 22
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k